Bonus Therapeutics Selected Amongst 100 Most Promising Innovative Technology Companies in Europe 

Bonus BioGroup is proud to announce that it was notified that Bonus Therapeutics Ltd., a wholly owned subsidiary of the Company, has been selected as a finalist for the 2015 edition of Red Herring’s Top 100 Europe Award.

 

The editorial team of Red Herring, a company which performs daily and periodical analytic reviews of technology companies around the world, has selected the 100 technology companies which, to the best of their judgement, demonstrate the greatest business opportunities across Europe. The nominees are evaluated on 20 quantitative and qualitative criteria, including proof of concept, technological innovation, market size, business strategy, management strength and financial performance.


Over the years, Red Herring’s experts have identified promising tech ventures which later reached leading positions in the area of their activities. Google, Yahoo!, Facebook, Twitter, Skype, YouTube, eBay and Mobileye, to name a few.


Bonus BioGroup is currently in the midst of a clinical trial designed to repair facial bone deficiencies, including upper and lower jawbone, through viable human bone transplants based on cells extracted from patients’ own fat tissue. The transplants are produced in the Company’s manufacturing facility at MATAM Advanced Technology Park in Haifa.
Bonus BioGroup’s unique technology combines various scientific disciplines such as biology, tissue engineering, material engineering and tailored medicine.